Skip to main content
NeuroThera Labs Inc. logo

NeuroThera Labs Inc. — Investor Relations & Filings

Ticker · NTLX ISIN · CA64136J1012 LEI · 529900GPL3C0DVADMS32 TSXV Manufacturing
Open in API
Filings indexed 145 across all filing types
Latest filing 2023-06-26 Regulatory Filings
Country CA Canada
Listing TSXV NTLX

About NeuroThera Labs Inc.

https://www.neurothera.com/

NeuroThera Labs Inc. is a clinical-stage company specializing in the development of therapeutics and advanced technologies for central nervous system (CNS) disorders and brain health. The company operates through two primary development streams. First, it is a leader in photobiomodulation (PBM) technology, developing drug-free, non-invasive devices for neurotherapy, targeting conditions such as Major Depressive Disorder (MDD), Alzheimer’s Disease, and Traumatic Brain Injury (TBI). Second, NeuroThera maintains a pharmaceutical pipeline focused on novel drug candidates, including programs based on THC and proprietary opioid/non-opioid compounds designed to enhance pain relief and treat CNS disorders. This dual approach leverages both advanced medical devices and clinical-stage drug candidates to address prevalent neurological conditions.

Recent filings

Filing Released Lang Actions
Interim MD&A - English.pdf
Regulatory Filings
2023-06-26 English
Interim financial statements/report – English.pdf
Regulatory Filings
2023-06-26 English
52-109FV1 - Certification of annual filings - CFO (E).pdf
Regulatory Filings Classification · 95% confidence The document is a 'Consent of Expert' letter related to a Base Shelf Prospectus dated May 31, 2023. It is a formal consent from a qualified person approving the use of technical disclosure in the Shelf Prospectus. The document does not contain financial statements, management discussion, or any report data. It is a regulatory filing related to securities compliance and expert consent, not a financial report or announcement of voting results, management changes, or capital updates. The document length is short (2074 characters) and is a formal attestation letter. Therefore, it fits best under Regulatory Filings (RNS) as a compliance document rather than a report or announcement category.
2023-05-31 English
52-109FV1 - Certification of annual filings - CEO (E).pdf
Regulatory Filings Classification · 100% confidence The document is a Form 52-109FV2, which is a Certification of Annual Filings Venture Issuer Basic Certificate. It is signed by the CEO certifying the review and fair presentation of the annual financial statements and MD&A for the financial year ended January 31, 2023. The document explicitly states it is a certification and does not contain the actual financial statements or detailed financial data. It is a regulatory attestation related to annual filings rather than the filings themselves. According to the Certification Rule, such officer certifications should be classified as Regulatory Filings (RNS) rather than as the Annual Report (10-K) or other financial reports. The document length is short (3015 characters), and it is primarily a certification letter, not the full report or announcement of a report publication. Therefore, the correct classification is Regulatory Filings (RNS).
2023-05-31 English
Annual MD&A - English.pdf
Management Reports Classification · 100% confidence The document is titled 'Management Discussion and Analysis' (MD&A) for the fiscal year ended January 31, 2023. It contains detailed explanations of the company's financial results, business description, share capital, stock options, liquidity, capital resources, related party transactions, legal proceedings, and other operational details. The MD&A is a management report that provides analysis and commentary on the financial statements and business trends. It is not an annual report (10-K), nor is it a simple announcement or certification. The length (15,000 characters) and content confirm it is a substantive management report. Therefore, the document fits the category of Management Reports (MDA).
2023-05-31 English
Audited annual financial statements – English.pdf
Annual Report Classification · 100% confidence The document is titled 'Financial Statements for the Year Ended January 31, 2023' and includes an Independent Auditor's Report, detailed financial statements (statements of financial position, loss and comprehensive loss, shareholders' equity, cash flows), and notes to the financial statements. The presence of an auditor's opinion, detailed financial data, and notes indicates this is a full annual financial report. The fiscal period covered is a full year ending January 31, 2023, consistent with an annual report. The document is about 15,000 characters, which is substantial and contains the actual financial data, not just an announcement or certification. Therefore, this document fits the definition of an Annual Report (10-K). FY 2023
2023-05-31 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.